Psychiatr. praxi. 2021;22(3):163-166 | DOI: 10.36290/psy.2021.034
Lurasidone in the treatment of pharmacoresistant schizophrenia: a case report
- Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové
- Psychiatrická klinika, Fakultní nemocnice Hradec Králové
Lurasidone is a serotonin and dopamine receptor antagonist, one of the most recently available antipsychotics in the Czech Republic. It has a minimal effect on physical and metabolic parameters while a significant effectiveness on the symptoms of psychosis is maintained. This is evidenced by the case report below, which describes a good response to lurasidone in a patient with paranoid schizophrenia and resistance to treatment, including electroconvulsive therapy.
Keywords: schizophrenia, drug resistance, lurasidone hydrochloride.
Published: October 14, 2021 Show citation
References
- Státní ústav pro kontrolu léčiv (SÚKL). Latuda. Ceny a úhrady. Informace o druhé úhradě ze zdravotního pojištění. 2021. Dostupný dne 11. 7. 2021 z: https://www.sukl.cz/modules/medication/detail.php?code=0194921 & tab=prices.
- Citrome L, Cucchiaro J, Sarma K, Phillips D, Silva R, Tsuchiya S, Loebel A. Long‑term safety and tolerability of lurasidone in schizophrenia: a 12-month, double‑blind, active‑controlled study. Int Clin Psychopharmacol 2012; 27(3): 165-176.
Go to original source... 
Go to PubMed... - Mattingly GW, Haddad PM, Tocco M, Xu J, Phillips D, Pikalov A, Loebel A. Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open‑label study. BMC Psychiatry 2020; 20(1): 199. Go to original source... Go to PubMed...
- Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010; 334(1): 171-181. Go to original source... Go to PubMed...
- PDSP Ki Database. Risperidone. 2021. Dostupný dne 11. 7. 2021 z: https://unc.live/2TXVbxe.
- Meltzer HY, Share DB, Jayathilake K, Salomon RM, Lee MA. Lurasidone Improves Psychopathology and Cognition in Treatment‑Resistant Schizophrenia. J Clin Psychopharmacol 2020; 40(3): 240-249. Go to original source... Go to PubMed...
- Taylor DM, Barnes TR, Young AH. The Maudsley prescribing guidelines in psychiatry. Hoboken, New Jersey: John Wiley & Sons 2021; 956 s. Go to original source...
- Schoretsanitis G, Kane JM, Correll CU, Marder SR, Citrome L, Newcomer JW, Robinson DG, Goff DC, Kelly DL, Freudenreich O, Piacentino D, Paulzen M, Conca A, Zernig G, Haen E, Baumann P, Hiemke C, Grunder G, American Society of Clinical P, Pharmakopsychiatrie T. Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry 2020; 81(3). Go to original source... Go to PubMed...
- Costamagna I, Calisti F, Cattaneo A, Hsu J, Tocco M, Pikalov A, Goldman R. Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double‑blind, placebo‑controlled 6-week studies. Eur Psychiatry 2021; 64(1): e35. Go to original source... Go to PubMed...
- Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A. Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. Eur Neuropsychopharmacol 2019; 29(9): 971-985. Go to original source... Go to PubMed...
- Huhn M, Nikolakopoulou A, Schneider‑Thoma J, Krause M, Samara M, Peter N, Arndt T, Backers L, Rothe P, Cipriani A, Davis J, Salanti G, Leucht S. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi‑episode schizophrenia: a systematic review and network meta‑analysis. Lancet 2019; 394(10202): 939-951. Go to original source... Go to PubMed...
- Greger J, Aladeen T, Lewandowski E, Wojcik R, Westphal E, Rainka M, Capote H. Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator. J Clin Psychopharmacol 2021; 41(1): 5-12. Go to original source... Go to PubMed...